BackProteostasis Therapeutics Overview

Proteostasis Therapeutics Receivables

Proteostasis Therapeutics's receivables is $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Proteostasis Therapeutics Receivables History

Loading

Proteostasis Therapeutics vs. peers: Receivables Comparison

Loading

Proteostasis Therapeutics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Proteostasis Therapeutics (PTI) FAQ

As of the most recent data (September 2020), PTI shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PTI's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Proteostasis Therapeutics is outperforming or lagging.

Tracking PTI's receivables over time shows whether Proteostasis Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Proteostasis Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.

Proteostasis Therapeutics's receivables is $0; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.